Immune checkpoint blockade combined with abnobaViscum therapy is linked to improved survival in advanced or metastatic non-small-cell lung cancer patients: a registry study in accordance with the ESMO guidance for reporting real-world evidence - Schad, Friedemann; Thronicke, Anja; Hofheinz, Ralf-Dieter; Klein, Reinhild; Grabowski, Patricia; Oei, Shiao Li; Wüstefeld, Hannah; Grah, Christian (Pharmaceuticals, 2024)
Gesehen am 17.04.2025